## Benznidazole

Cat. No.:	HY-B1548		
CAS No.:	22994-85-0		
Molecular Formula:	C <sub>12</sub> H <sub>12</sub> N <sub>4</sub> O	3	
Molecular Weight:	260.25		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (192.12 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	3.8425 mL	19.2123 mL	38.4246 mL		
		5 mM	0.7685 mL	3.8425 mL	7.6849 mL		
		10 mM	0.3842 mL	1.9212 mL	3.8425 mL		
	Please refer to the so	lubility information to select the ap	propriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (7.99 mM); Clear solution						

BIOLOGICAL ACTI	
DIOLOGICALACIA	
Description	Benznidazole (Ro 07-1051) is an antiparasitic medication, with an IC <sub>50</sub> of 20.35 μM for Colombian T. cruzi strains, and has been used in the treatment of Chagas disease <sup>[1][2]</sup> .
In Vivo	Benznidazole (100 mg/kg/day, p.o., 30 days) produces a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart, in mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12 isolate and treated at 180 days post infection (p.i.) (i.e. chronic phase) with Benznidazole <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## Product Data Sheet

Ν Η

0-

`O⁻



Animal Model:	Mice infected with Trypanosoma cruzi Tulahuen strain or SGO-Z12 <sup>[1]</sup>
Dosage:	100 mg/kg/day
Administration:	Orally for 30 days
Result:	Produced a decrease in electrocardiographic alterations, fewer modifications in the affinity and density of cardiac-receptors, and few isolated areas of fibrosis in the heart.

## CUSTOMER VALIDATION

- Nat Commun. 2023 Oct 25;14(1):6769.
- bioRxiv. 2023 Jul 12.
- Research Square Print. 2023 Jan 20;rs.3.rs-2497474.

See more customer validations on www.MedChemExpress.com

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA